Investigational data from long-term, follow-up studies showed that olipudase alfa provided sustained improvement in lung function (as measured by DLco) and reduction of spleen and liver volumes over time in… Read More
Phase 3 trial reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more… Read More
VANCOUVER, B.C. — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2021 financial results after market… Read More
The audit, consulting and tax services company is expanding its business ConvergeHEALTH and launching two other businesses in the consumer and financial sectors. It’s investing in everything from new software… Read More
ZT-01 restored glucagon secretion, and reduced the frequency and severity of hypoglycemia in preclinical model of insulin-induced hypoglycemia TORONTO — Zucara Therapeutics Inc., a diabetes life sciences company developing the… Read More
